This review looks at host-directed therapy, or HDT, as a way to help the body fight tuberculosis. Instead of just attacking the bacteria, these treatments aim to improve the body's own immune response and reduce the damage caused by the infection. The review specifically highlights the potential of repurposing existing medications, such as metformin and statins, to support this process.
While these treatments show promise in laboratory and animal models, it is important to note that much of the evidence comes from other diseases rather than directly from tuberculosis studies. There are still significant gaps in knowledge when it comes to moving these treatments from the lab into actual clinical practice for patients.
Because the evidence is currently based on early research and models, these findings are not yet ready to change standard medical care. The goal of this research is to create a framework for future studies to determine which specific approaches might eventually help patients with tuberculosis.
